S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:PULM

Pulmatrix (PULM) Stock Price, News & Analysis

$1.75
+0.13 (+8.02%)
(As of 03/28/2024 ET)
Today's Range
$1.56
$1.85
50-Day Range
$1.62
$2.01
52-Week Range
$1.55
$3.15
Volume
38,150 shs
Average Volume
17,331 shs
Market Capitalization
$6.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Pulmatrix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
471.4% Upside
$10.00 Price Target
Short Interest
Healthy
0.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Pulmatrix in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.79 out of 5 stars

PULM stock logo

About Pulmatrix Stock (NASDAQ:PULM)

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

PULM Stock Price History

PULM Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com
Cipla Ltd CIPLA
Pulmatrix shuts down study, explores sale
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Pulmatrix Inc PULM
Pulmatrix Down on Q3 Results
Aspergillosis Treatment Research Report 2023
See More Headlines
Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/29/2022
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PULM
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+471.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-18,840,000.00
Net Margins
-238.89%
Pretax Margin
-238.89%

Debt

Sales & Book Value

Annual Sales
$6.07 million
Book Value
$8.55 per share

Miscellaneous

Free Float
3,520,000
Market Cap
$6.39 million
Optionable
Not Optionable
Beta
0.95
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Teofilo David Raad MBA (Age 54)
    President, CEO & Director
    Comp: $772.7k
  • Mr. Peter Ludlum CMA (Age 69)
    MBA, Interim CFO and Principal Accounting & Financial Officer
    Comp: $398.58k
  • Dr. Margaret M. Wasilewski M.D. (Age 67)
    Chief Medical Officer
    Comp: $585.84k
  • Dr. Alexander M. Klibanov Ph.D. (Age 74)
    Founder

PULM Stock Analysis - Frequently Asked Questions

Should I buy or sell Pulmatrix stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PULM shares.
View PULM analyst ratings
or view top-rated stocks.

What is Pulmatrix's stock price target for 2024?

1 brokers have issued 1 year price targets for Pulmatrix's shares. Their PULM share price targets range from $10.00 to $10.00. On average, they anticipate the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 471.4% from the stock's current price.
View analysts price targets for PULM
or view top-rated stocks among Wall Street analysts.

How have PULM shares performed in 2024?

Pulmatrix's stock was trading at $1.86 at the beginning of 2024. Since then, PULM stock has decreased by 5.9% and is now trading at $1.75.
View the best growth stocks for 2024 here
.

Are investors shorting Pulmatrix?

Pulmatrix saw a drop in short interest in March. As of March 15th, there was short interest totaling 400 shares, a drop of 97.4% from the February 29th total of 15,300 shares. Based on an average daily trading volume, of 17,900 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are short sold.
View Pulmatrix's Short Interest
.

When is Pulmatrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our PULM earnings forecast
.

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) issued its quarterly earnings results on Tuesday, March, 29th. The biotechnology company reported ($2.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.60) by $0.83. Pulmatrix had a negative trailing twelve-month return on equity of 64.09% and a negative net margin of 238.89%.

When did Pulmatrix's stock split?

Pulmatrix shares reverse split on the morning of Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).

Who are Pulmatrix's major shareholders?

Pulmatrix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.96%), Vanguard Group Inc. (0.96%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Pulmatrix?

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PULM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners